Neurodegenerative Disease Therapeutics Market Outlook: Market to Reach US$ 28.78 Billion by 2033 at 9.8% CAGR; North America Leads with 44% Share; Key Players Include Pfizer, Novartis, and Roche

Neurodegenerative Disease Therapeutics Market reached US$ 12.52 billion in 2024 and is projected to expand to US$ 28.78 billion by 2033, growing at a CAGR of 9.8% during the forecast period 2025-2033. The market is experiencing robust growth driven by the rising global burden of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis. Rapid population aging, increasing life expectancy, and improved diagnostic capabilities are contributing to higher disease detection rates, thereby increasing demand for long-term and disease-modifying therapies. Additionally, growing healthcare expenditure and heightened awareness of neurological disorders are further supporting market expansion.

Pharmaceutical and biotechnology companies are increasingly focusing on innovative therapeutic approaches, including disease-modifying drugs, gene therapies, RNA-based treatments, and neuroprotective agents, to address the unmet clinical needs in neurodegenerative diseases. Strategic collaborations, licensing agreements, and pipeline expansion initiatives are accelerating product development and commercialization. For example, in December 2024, Novartis entered into a global licensing and partnership agreement with PTC Therapeutics to advance PTC518, an investigational oral therapy for Huntington's disease, underscoring the industry's commitment to advancing novel treatments. Continued progress in biomarker discovery, precision medicine, and clinical trial design is expected to further drive innovation and growth in the neurodegenerative disease therapeutics market over the forecast period.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/neurodegenerative-disease-therapeutics-market?sai-v

The Neurodegenerative Disease Therapeutics Market is the sector that develops and supplies drugs and treatment solutions aimed at managing, slowing, or treating disorders such as Alzheimer's, Parkinson's, and Huntington's disease.

Key Developments
✅ October 2025: Healthcare providers in North America prescribed approved therapeutics for Alzheimer's disease, Parkinson's disease, and multiple sclerosis across hospital and specialty clinic settings.

✅ September 2025: European healthcare systems administered disease-modifying therapies and symptomatic treatments for neurodegenerative disorders under clinical practice guidelines.

✅ August 2025: Asia-Pacific hospitals used oral, injectable, and infusion-based neurodegenerative disease therapies in neurology departments.

✅ July 2025: Pharmaceutical companies conducted regulated clinical trials evaluating small molecules, biologics, and gene-based therapies for neurodegenerative conditions.

✅ May 2025: Neurology research centers applied biomarker-based assessments to monitor treatment response in neurodegenerative disease patients.

✅ March 2025: Regulatory agencies reviewed safety, efficacy, and post-market surveillance data for approved neurodegenerative disease therapeutics.

Mergers & Acquisitions
✅ November 2025: A global pharmaceutical company acquired a neuroscience-focused biotech firm to expand its neurodegenerative disease therapy pipeline.

✅ August 2025: A European biopharmaceutical company partnered with a research institute to co-develop therapeutics targeting neurodegenerative disorders.

✅ June 2025: An Asia-Pacific pharmaceutical firm acquired rights to a neurodegenerative disease drug candidate to strengthen its neurology portfolio.

Key Players
AbbVie Inc. | Amneal Pharmaceuticals LLC | Eisai Co., Ltd. | F. Hoffmann-La Roche Ltd | Merck KGaA | Novartis AG | Pfizer Inc. | Teva Pharmaceutical Industries Ltd. | Otsuka Pharmaceutical Co., Ltd. | Orion Corporation

Key Highlights

Pfizer Inc. - Holds a share of 18.5 percent: Leads the market with a broad pharmaceutical portfolio, strong global distribution networks, and sustained investment in branded and specialty therapies.

Novartis AG - Holds a share of 16.2 percent: Maintains a strong position through innovative medicines, generics, and biosimilars, supported by robust R&D capabilities and global reach.

F. Hoffmann-La Roche Ltd - Holds a share of 14.7 percent: Drives market presence via specialty pharmaceuticals and precision medicine approaches across oncology, neurology, and immunology.

AbbVie Inc. - Holds a share of 12.9 percent: Benefits from blockbuster therapies and a focused strategy in immunology, neuroscience, and hematologic oncology.

Merck KGaA - Holds a share of 9.6 percent: Strengthens its position through specialty pharmaceuticals and life science-linked drug development capabilities.

Teva Pharmaceutical Industries Ltd. - Holds a share of 8.4 percent: A key generics player with large-scale manufacturing, cost efficiencies, and a diversified global product portfolio.

Eisai Co., Ltd. - Holds a share of 6.5 percent: Focused on neurology and oncology therapeutics, with strong expertise in CNS-related drug development.

Otsuka Pharmaceutical Co., Ltd. - Holds a share of 5.1 percent: Supports growth through CNS, metabolic, and specialty pharmaceutical products with steady international expansion.

Amneal Pharmaceuticals LLC - Holds a share of 4.2 percent: Expands market presence through generics and specialty medicines, particularly in cost-sensitive markets.

Orion Corporation - Holds a share of 3.9 percent: Regional player with strengths in CNS and oncology therapeutics, contributing to niche market segments.

Others - Holds a share of 0.0 percent: Includes smaller regional and emerging pharmaceutical companies supporting competitive market dynamics.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=neurodegenerative-disease-therapeutics-market?sai-v
(Purchase 2 or more Reports and get 50% discount.)

Market Drivers
- Rising prevalence of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS).

- Growing aging population globally with increased susceptibility to cognitive and motor neurodegenerative conditions.

- Expanding understanding of disease mechanisms driving development of targeted therapies and biomarkers.

- Advancements in biologics, small molecules, gene therapies, and immunotherapies for neurodegenerative indications.

- Increasing investments in clinical research, biotech innovation, and precision medicine approaches.

- Supportive regulatory pathways and accelerated approval programs for breakthrough therapies.

- Growing demand for improved disease-modifying treatments and symptomatic relief options.

Industry Developments
- Launch and clinical progression of novel small-molecule drugs targeting key pathological pathways such as tau, amyloid, alpha-synuclein, and neuroinflammation.

- Advancements in biologic therapeutics including monoclonal antibodies, neuroprotective agents, and growth factor modulation.

- Expansion of gene therapy and RNA-based therapeutic pipelines for genetic neurodegenerative disorders.

- Integration of biomarkers and digital tools to improve patient stratification, trial design, and outcome measures.

- Strategic collaborations between biopharma companies, academic research centers, and biotech startups.

- Increased mergers, acquisitions, and funding to accelerate late-stage development programs.

- Development of combination therapy approaches targeting multiple disease mechanisms.

Regional Insights
North America - 44% share: "Driven by high prevalence of neurodegenerative diseases, advanced research infrastructure, strong clinical trial activity, and supportive regulatory environment."

Europe - 28% share: "Supported by robust healthcare systems, active neuroscience research networks, and increasing adoption of innovative therapeutics."

Asia Pacific - 23% share: "Fueled by growing elderly population, rising disease awareness, expanding healthcare access, and increased clinical research investments."

Latin America - 3% share: "Boosted by improving healthcare infrastructure, growing awareness of neurodegenerative conditions, and emerging therapeutic adoption."

Middle East & Africa - 2% share: "Driven by healthcare system modernization efforts, increasing diagnostic capabilities, and gradually growing access to advanced therapies."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/neurodegenerative-disease-therapeutics-market?sai-v

Key Segments
By Drug Class
Dopamine agonists account for a significant share of the market as they are widely prescribed for managing motor symptoms, particularly in Parkinson's disease, by directly stimulating dopamine receptors. Decarboxylase inhibitors play a critical role in combination therapies by enhancing the bioavailability of dopamine and reducing peripheral side effects, supporting their sustained demand. Cholinesterase inhibitors are extensively used in the treatment of cognitive decline, especially in Alzheimer's disease, driving steady market growth. Immunomodulators are gaining traction due to increasing research into neuroinflammation and immune-mediated mechanisms in neurodegenerative disorders. Other drug classes, including neuroprotective agents and combination therapies, contribute to market expansion by addressing unmet clinical needs.

By Disease Type
Parkinson's disease represents the largest disease segment, driven by its high prevalence, chronic nature, and long-term pharmacological management requirements. Amyotrophic lateral sclerosis (ALS) holds a smaller but clinically significant share, supported by ongoing drug development efforts and orphan drug designations. Alzheimer's disease is witnessing robust growth due to rising global incidence, aging populations, and increasing demand for disease-modifying and symptomatic therapies. Huntington disease constitutes a niche segment, characterized by limited treatment options and ongoing research activities. Other neurodegenerative diseases contribute steadily to market growth through expanding diagnostic rates and therapeutic interventions.

By Route of Administration
Oral administration dominates the market owing to its convenience, high patient compliance, and widespread availability of tablet and capsule formulations. Injectable therapies are experiencing steady growth, particularly for advanced-stage diseases and biologic-based treatments requiring controlled dosing. Transdermal routes are gaining adoption as they provide sustained drug release, improved adherence, and reduced systemic side effects, especially in chronic neurological conditions.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.